A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors

Cancer

Volumn 107, Issue 11, 2006, Pages 2688-2697

  Ryan, David P ^a,f   O'Neil, Bert H ^b   Supko, Jeffrey G ^a   Lima, Carlo M Rocha ^c   Dees, E Claire ^b   Appleman, Leonard J ^d   Clark, Jeffrey ^a   Fidias, Phinos ^a   Orlowski, Robert Z ^b   Kashala, Oscar ^e   Eder, Joseph P ^d   Cusack Jr , James C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bortezomib; Colorectal cancer; Irinotecan; Proteasome inhibitor; Solid tumors

Indexed keywords

ANTIEMETIC AGENT; BORTEZOMIB; COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; PROTEASOME;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANDIDIASIS; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE CALCULATION; DRUG DOSE REGIMEN; DYSPNEA; ESOPHAGUS CANCER; ESOPHAGUS CANDIDIASIS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERAMYLASEMIA; HYPESTHESIA; HYPONATREMIA; INFECTION; LEUKOCYTE COUNT; LEUKOPENIA; LIMB PAIN; LUNG CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUSCULOSKELETAL DISEASE; NAUSEA; NEURALGIA; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PANCREAS CANCER; PARESTHESIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEAKNESS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CAMPTOTHECIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 33751563004     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22280     Document Type: Article

References (30)

1. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7:9-16.
2. Cusack JC Jr., Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001;61:3535-3540.
3. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
4. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res. 2003;9:1145-1154.
5. An B, Guldfarb RH, Siman R, Don QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Diff. 1998;5:1062-1075.
6. Blagosklonny MV, Wu GS, Omura S, el Deiry WS. Proteasome-dependent regulation of p21WAF1/C1P1 expression. Biochem Biophys Res Commun. 1996;227:564-569.
7. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377-2380.
8. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8:2505-2511.
9. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420-4427.
10. Stevenson J, Nho CW, Schick J, et al. Phase II clinical/pharmacodynamic trial of the proteasome inhibitor PS-341 in advanced non-small cell lung cancer [abstract 810]. Proc Am Soc Clin Oncol. 2003;22:202.
11. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165-172.
12. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
13. Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol. 2004;22:3720-3725.
14. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
15. Twombly R. First proteasome inhibitor approved for multiple myeloma [abstract]. J Natl Cancer Inst. 2003;95:845.
16. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002;8:641-661.
17. Pfizer Inc.Camptosar (brand of irinotecan hydrochloride injection) prescribing information. Available at: http://www.pfizer.com/download/ uspi_camptosar.pdf. 2004.
18. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem. 2001;82:110-122.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.
20. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PI. Proteasome inhibition measurements: clinical application. Clin Chem. 2000;46:673-683.
21. Rasheed Z, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene. 2003;22:7296-7304.
22. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996;14:1128-1135.
23. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 1997;15:625-631.
24. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2108-2121.
25. Kawabata S, Oka M, Shiozawa K, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun. 2001;280:1216-1223.
26. Di Nicolantonio F, Mercer SJ, Knight LA, et al. Cancer cell adaptation to chemotherapy. BMC Cancer. 2005;5:78.
27. Norris MD, Smith I, Tanabe K, et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther. 2005;4:547-553.
28. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13:1841-1851.
29. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001;61:5926-5932.
30. Catley L, Tai YT, Shringarpure R, et al. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res. 2004;64:8746-8753.